|
Wintergirl
Student

Registered: 03/19/22
Posts: 104
Loc: Home Planet
|
5-HT2B receptor and potential cardiac impacts
#28183456 - 02/12/23 06:45 AM (11 months, 9 days ago) |
|
|
This was in the New York Times today and is the first time I've heard of a potential link between psychedelics and heart valve issues. But the research they cite is from 2007 and we have the benefit of long-term, large scale, real world experience. If this was a problem, we'd know about it, right? Is there any actual evidence that people who microdose are more prone to heart disease?
"Most hallucinogens are thought to produce their psychedelic effects by activating a specific serotonin receptor called 5-HT2A (except ketamine, which primarily works via the glutamate system). The drugs also act on a sibling serotonin receptor, 5-HT2B, which has been linked to valvular heart disease. Research has shown that medications that activate this receptor — which include some used to treat Parkinson’s disease and migraines, as well as the infamous diet drug fen-phen — cause valvular damage in roughly 25 percent of people who take them. Two small studies of frequent, heavy users of MDMA (another psychedelic-related drug that activates 5-HT2B) showed the same signs of heart disease."
https://www.nejm.org/doi/10.1056/NEJMp068265 https://pubmed.ncbi.nlm.nih.gov/17950805/
|
Lithop
Spaghetti Days



Registered: 04/09/22
Posts: 764
Loc: 🛸
|
Re: 5-HT2B receptor and potential cardiac impacts [Re: Wintergirl]
#28183572 - 02/12/23 08:22 AM (11 months, 9 days ago) |
|
|
Quote:
Wintergirl said: If this was a problem, we'd know about it, right?
I don't know about it, you dont know about it but someone out there might be worried about it right now!
There was a thread recently, about micro-dosing and heart concerns in which a user summed it up best, IMO:
Quote:
GenericHero said: Several medications with relatively strong 5HT2B receptor binding affinity (Ki < 500 nM) have been unquestionably associated with VHD, such as methylergonovine, methysergide, ergotamine, pergolide, cabergoline, fenfluramine (active metabolite norfenfluramine); where roughly 25% of patients developed new onset VHD, including some cases of heart valve thickening that required heart surgery and resulted in death.
a recent FDA regulatory forum toxicology expert review article has suggested that a medication’s 5HT2B binding affinity (Ki) was considered a better predictor of VHD risk than measures of functional activity such as EC50.
LSD and psilocybin (active metabolite psilocin) present concerns for VHD because they too bind to the 5HT2B receptor. Unfortunately, these psychedelics could potentially cause VHD when “microdosed” for many months to years.
Seems pretty straightforward to me.
Make of that what you will. Cheers!
--------------------
🌬️ 🌻 ➞➞➞ ❮❮❮❮ 🌈 ❹⑤⓿ 🌬️ 🌻 ➞➞➞ ❮❮❮❮ 🌈 ❹⑤⓿ 🌬️ 🌻 ➞➞➞ ❮❮❮❮ 🌈 ❹⑤⓿
|
Dave Bowman
Albert Hoffmans Apprentice




Registered: 08/30/07
Posts: 2,104
Loc: Your Imagination
Last seen: 3 months, 22 days
|
Re: 5-HT2B receptor and potential cardiac impacts [Re: Lithop]
#28183612 - 02/12/23 08:46 AM (11 months, 9 days ago) |
|
|
Guess it's time for a break
|
|